You are here:
ARGX-110
Acute myeloïde leukemie (AML)
No judgement
Clinical trials
Cusatuzumab
Oncology and Hematology
New medicine (specialité)
AML / MDS
Janssen
Other
Intravenous
Intravenous drip
Intermural (MSZ)
Cusatuzumab is ontworpen om: CD70 te blokkeren en kankercellen die CD70 tot expressie brengen te doden door: complementafhankelijke cytotoxiciteit, verbeterde antilichaamafhankelijke celgemedieerde fagocytose en verbeterde antilichaamafhankelijke celgemedieerde cytotoxiciteit en het herstel van het immuunsysteem tegen solide tumoren.
Centralised (EMA)
April 2021
April 2022
2 times every 4 weeks
10mg/kg - 20 mg/kg
NCT04023526
< 774
Market share is generally not included unless otherwise stated.
NKR
In 2017 waren er 774 patiënten met AML.
There is currently nothing known about the expected cost.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
No
Geen indicatie-uitbreidingen op korte termijn. Wel in fase I/II voor: "Cutaneous T-cell lymphoma Haematological malignancies; Myelodysplastic syndromes; Solid tumours".
There is currently no futher information available.
Understanding of expected market entry of innovative medicines